Telomere pathway is a well-validated target at the preclinical level, encouraging the evaluation of therapeutic combined option in future clinical protocols. In this context, we have recently reported a specific link between the telomere-targeting agent RHPS4 and chemosensitivity toward camptothecins in colorectal tumors.
Introduction
Guanine-rich stretches of DNA have a high propensity to self-associate into planar guanine quartets to give unusual structures (1) called G-quadruplexes (G4). Quadruplexes are thought to play important roles in some biological events because many guanine-rich regulative regions in the human genome possess the potential to adopt a quadruplex conformation. The conformations of G4 provide selective recognition sites for small molecules and thus these structures have become important drug-design targets for the treatment of various human disorders. Two drugs acting on nucleolin that either target a G4 (CX-3543 or Quarfloxin) or fold into a G4 structure (AS1411) are in Phase II clinical trials against cancer (2,3).
The specific nucleoprotein structure encountered at telomeres controls the terminal replication of chromosomal DNA and protects from the DNA damage checkpoint machinery and repair (4, 5) . Telomeric DNA is composed of the repetition of a small G-rich motif (TTAGGG in human cells), ends as a single stranded tail on the 3'-oriented strand (G-tail) and is transcribed into a UUAGGG repeats containing RNA called TERRA (6) .
Telomeric DNA can fold into non-canonical structures such as t-loops (7) and G4 DNA (8) .
Both in vitro and in vivo data strongly support the physiological relevance of telomeric G4 DNA (8) . An unfolded 3' overhang is required for an optimal telomerase reaction and G4 formation has been shown to inhibit telomere elongation in vitro (9) .
In human cells, the complete replication of telomeric DNA usually depends on telomerase, a specialized reverse transcriptase that uses its RNA template to add G-rich telomeric repeats to the terminal 3' overhang (10) . In preclinical studies, telomerase inhibitors have shown promise as effective antitumor agents against a variety of human tumors. These translational advances have resulted in the first antitelomerase agent, the oligonucleotidebased GRN163L targeting the telomerase RNA template, completing Phase I/II clinical studies (11) . Inhibition of Topo I stabilizes telomere damage
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The inability of telomerase to utilize a G4 folded telomeric substrate has led to the emergence of a novel strategy for cancer therapy. G4-interacting agents are small molecules able to bind and stabilize the telomeric DNA in a quadruplex conformation, thereby inhibiting telomere extension by telomerase (12) . Interestingly, G4-interacting compounds might disrupt telomere architecture, both in telomerase-and ALT-positive tumors, causing immediate and profound effects on cell proliferation (13) . Over the past decade, many chemical classes of G4 ligands have been described. Several of them reduce the growth of various cancer cell lines in vitro, often accompanied by cellular senescence and/or apoptosis, and can be considered as telomere-damage inducers as evidenced by the characteristic DNA damage response (i.e., the appearance of γH2AX foci) at the telomeres. Moreover, some of them exhibit antitumoral activity in mice bearing various human tumor xenografts (14) (15) (16) (17) . It is encouraging for future clinical applications that several G4 ligands show in vivo synergistic activity with some conventional cytotoxic agents (18) (19) (20) (21) . RHPS4 (3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate) is one of the most effective and selective G4 ligands. Our previous studies revealed that this agent, by stabilizing G4 DNA at telomeres, impairs fork progression and/or telomere processing resulting in telomere damages (16, 22) . Telomere dysfunction is the major cause of RHPS4 toxicity since POT1 or TRF2 overexpression is sufficient to overcome the deleterious effects of RHPS4 on cellular proliferation and DNA damage (16) . In agreement with the view that the telomere specific effects of RHPS4 is due to G4 stabilization, RHPS4 selectivity binds to quadruplex vs duplex DNA (23) . Interestingly in view of clinical application, RHPS4 is active in vivo as a single agent with a good toxicological profile (16, 20 Inhibition of Topo I stabilizes telomere damage 6 activity, which are widely used in the therapy of different types of cancer, might synergize with anti-telomere strategies. Camptothecins are Topoisomerase I (Topo I) inhibitor chemotherapeutic agents and analogs such as irinotecan and topotecan are approved for treatment of many types of solid tumors such as lung, colorectal, ovarian, cervical and gastric carcinomas. Unfortunately they are not curative as single agents. To improve the efficacy of Topo I inhibitors several approaches could be pursued including development of new camptothecins with a more favorable therapeutic profile and their combination with other cytotoxic agents and/or molecularly targeted agents, on the basis of the knowledge of the mechanisms of tumor cells response (25) . The convergence of these efforts could result in more effective anticancer therapies.
In this context, we recently reported that antitumor efficacy of camptothecins is increased when used in combination with the G4 ligand RHPS4 (20) . On the basis of these results, the aim of the present study was to investigate the mechanism(s) involved in this specific drug interaction by using well-characterized G4 ligands and standard or novel Topo I inhibitors (26) (27) (28) (29) .
Research. IDN5174 was supplied by INDENA (Milan, Italy). The G4 ligands RHPS4, CORON and PIP-PIPER(1,7), were synthesized as previously described (23, 32) .
Cell lines and culture conditions.
BJ fibroblasts expressing hTERT and SV40 early region (BJ-HELT) were maintained as previously described (33). HT29 and HCT116 colorectal adenocarcinoma cells were obtained and maintained as previously reported (20) .
Cytotoxic assay
Cells were seeded at a density of 5 x 10 4 cells/plate and exposed 24 hrs later to the 
Chromatin Immunoprecipitation assay (ChIP)
BJ-HELT fibroblasts were treated for 24 hrs with 0.5 μM RHPS4, 0.05 μM CORON and 4
μM PIP-PIPER(1,7), or for 2 hrs with 0.5 μM SN-38. ChIP assay was performed as previously described (16) . The following antibodies were used: pAbs anti-Topo I, Topo IIα and Topo IIIα (Abcam Ltd.; Cambridge UK). mAb anti-β-actin (Sigma, Chemicals, Milano, Italy) was used as negative control of the ChIP assay.
Immunofluorescence analysis
Research. Inhibition of Topo I stabilizes telomere damage 8 BJ-HELT fibroblasts were treated with 0.5 μM SN-38 for 2 hrs and 0.5 μM RHPS4 for 48 hrs alone or in combination. Cells were processed for IF as previously reported (22) 
Cell cycle analysis and apoptosis
Cell cycle analysis was performed by flow cytometry (Becton-Dickinson, Heidelberg, Germany) as previously reported (34). Apoptotic cells were scored by Hoechst staining.
Antitumor activity
CD-1 male nude (nu/nu) mice, 6-8 weeks old were purchased from Charles River Laboratories (Calco, Italy). All procedures involving animals and their care were conducted as previously reported (35). RHPS4 was given i.v. at 10 mg/Kg/d for fifteen consecutive days and ST1481 was administered per os at 1.5 mg/kg q4dx4 times, based on previous results (20, 36) . In particular, nude mice were injected with HT29 at 3 x 10 6 cells/mice and treatments were started when a tumor mass of about 600 mg was evident in the mice. In the combination experiments the two drugs were administered with an interval of 24 hrs. The tumor weight was calculated from caliper measurements (37) and antitumor efficacy of treatments was assessed as previously reported (20) .
Immunohistochemical analysis
Activation of damage response was determined immunohistochemically by using mAb anti-γH2AX (Upstate) as previously reported (16) . The number of γH2AX-positive cells were counted in eight high-power fields (400x magnification) per section and reported as γH2AX-positive nuclei/mm 2 . Two independent observers did the counts in blinded fashion.
Statistical analysis.
Research.
on October Inhibition of Topo I stabilizes telomere damage 9 Synergism, additivity, and antagonism were assessed by isobologram analysis using the Chou-Talalay method as previously described (20) . Combination index (CI) values <0.9, >0.9 < 1.2, and >1.2 indicate synergism, additive effect, and antagonism, respectively. Student's t test (unpaired, two-tailed) was used for statistical comparison of differences.
Survival curves of mice were generated by Kaplan-Maier product-limit estimate, and statistical differences between the various groups were evaluated by log-rank analysis with
Yates correction (software Primer of Biostatistics; McGraw-Hill, New York, NY).
Differences were considered statistically significant when p<0.05. The binding to telomeric DNA of Topo IIIα, a topoisomerase of Topo I family, was also increased in RHPS4-treated sample ( Figure 3A) , consistently with the ability of this G4 ligand to activate the helicase BLM (22) . In agreement with previous studies (24), we detect the presence of Topo IIα at the telomeres of untreated cells. However, in contrast to Topo I, we do not observed any enrichment of Topo IIα at telomeric regions. We conclude that G4 ligands trigger a DNA damage that specifically requires the Topoisomerase I, providing an explanation for the strong synergistic interaction we observed between G4 ligands and camptothecin.
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We finally evaluated the interaction between the G4 ligand RHPS4 and three novel camptothecins with a more favorable therapeutic and pharmacological profile than clinically used camptothecins, including IDN5174, ST1968 and ST1481. As reported in Figure 5A , the treatment with camptothecins followed by RHPS4 was highly effective as revealed by the reduction of survival of HT29 cells by one to three order of magnitude, depending on the camptothecin used. Again, this effect was markedly dependent on the sequence employed, since the opposite sequence of treatment produced only a slight reduction of clonogenic ability. The results have been confirmed in another coloncarcinoma line ( Figure 5B ) and the analysis of these data by using the CI confirmed that the optimal sequence has a strong synergistic effect on cell survival ( Figure 5C-D) .
Based on in vitro results, experiments were performed in vivo on HT29 tumor-bearing mice. In particular, we focused our attention to the combination of RHPS4 with ST1481, an orally bioavailable camptothecin currently undergoing clinical trials. ST1481 confirmed its relevant antitumor efficacy, being tumor weight significantly reduced (P < 0.001) compared to untreated and to mice treated with RHPS4 alone ( Figure 6A and Supplemental Table I ).
The combination with RHPS4 produced an improved therapeutic efficacy as it is evident by the tumor growth delay of 33 days, significantly increased compared to ST1481 (24 days, P= 0.004) and to RHPS4 ( 6 days, P< 0.001) alone, and by the complete tumor regression in half of the treated mice ( Figure 6A and Supplemental Table I ). This inhibitory effect on tumor growth of combination treatment led to a marked increase in the survival of mice significantly higher (P< 0.001) compared to any single treatment groups ( Figure 6B and Supplemental Table I ). Of note, a further improved antitumor efficacy has been observed when a second cycle of treatment was administered. Mice receiving two cycles of treatment had a significant advantage (P < 0.001) in terms of reduction of tumor mass and this effect persisted for almost 2 months (55 days in T-C and nearly 100% complete response rate in 7 out of 8 mice). This marked and prolonged antitumor effect produced an 
Discussion
Stabilization of telomeric G4 can be considered an original strategy for controlling tumor growth, making G4 ligands attractive potential anticancer agents (38) . We recently showed that one of them, the RHPS4 molecule, has an antitumor effect, by selectively inducing telomere damage in xenografted tumor models. More recently, we have uncovered a specific link between RHPS4 and chemosensitivity toward camptothecins in colorectal tumors. In the present study we have investigated the mechanism(s) involved in this specific drug interaction.
We confirmed the strong synergistic interaction between camptothecin and RHPS4 by using other G4 ligands and novel camptothecin analogues, clearly demonstrating that the synergistic effect between Topo I inhibitors and telomere-targeting agents is a general phenomenon. These results have been obtained by using cytotoxic doses of camptothecins, able to reduce cell viability and induce DNA damage, and therefore they are reasonably ascribed to topoisomerase I-mediated effects. Strikingly, the best synergistic drug interaction is observed if camptothecins are given before G4 ligands. Thus, campthotecin-treated cells are either more prone to be damaged by RHPS4 or less efficient to repair RHPS4-dependent damages or both. In favor of the second possibility, we did not observe an increased rate of damage due to RHPS4 in camptothecin-treated cells as compared to controls but rather a persistence of the damage. This suggests that Topo I is normally required to repair the telomeric damages elicited by G4-ligands and that its inactivation by camptothecin prevents or impairs this repair. In agreement with this hypothesis, we found that Topo I is enriched at telomeres of RHPS4-tretaed cells. This unveils a function of Topo I at telomeres in relation with G4 formation. These results, together with in vitro results showing that Topo I binds to G4 tetraplexes (39) and functionally interacts with the Werner helicase (40) that unwinds these DNA structures (41) , suggest that in vivo Topo I resolves the G4 tetraplexes that either reduced four days after the end of ST1481 treatment, it was still high when ST1481 was followed by RHPS4 administration.
In conclusion, our studies provide a compelling argument to suggest that the integration of G4 ligands to camptothecin-based treatment might be a highly valuable therapeutic combination. Assaying for the persistence of DNA damage response in tumor might be used as a surrogate marker of tumor response. 
